Clinical Trial Update: Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim [Phase 2]

View source ↗

Summary

A Phase 2 hematopoietic stem cell transplantation trial in children with severe combined immunodeficiency using alemtuzumab, plerixafor, and filgrastim was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Mozobil (plerixafor)
• Neupogen (Filgrastim)

Snippet

Sponsor: University of California, San Francisco | Conditions: Severe Combined Immunodeficiency | Phase 2 | Status: TERMINATED | Results posted: 2014-11-10